Sun Pharma launches lipid disorders drug Ezallor Sprinkle™ in the U.S.
Category: #health  By Pankaj Singh  Date: 2019-07-15
  • share
  • Twitter
  • Facebook
  • LinkedIn

Sun Pharma launches lipid disorders drug Ezallor Sprinkle™ in the U.S.

Ezallor Sprinkle™ (rosuvastatin) capsules can be indicated for three lipid disorders in conjunction with patient’s diet.

Indian pharma giant, Sun Pharmaceutical Industries Ltd. has recently announced the U.S. launch of Ezallor Sprinkle™ (rosuvastatin) capsules, a drug designed specifically to treat patients with elevated lipid disorders.

According to sources, Ezallor Sprinkle is indicated as an adjunct to diet for treating adults with hypertriglyceridemia, primary dysbetalipoproteinemia (type III hyperlipoproteinemia), and other lipid-lowering treatments like LDL apheresis. It also acts as a monotherapy to lower LDL-C, total cholesterol, and ApoB in patients with homozygous familial hypercholesterolemia.

Speaking on the launch, Abhay Gandhi, CEO, North America, Sun Pharma, said that their firm, with Ezallor Sprinkle, will continue on its commitment to provide a portfolio of alternative formulation products that address the needs of patients facing difficulty in swallowing, which is particularly prevalent among residents in long-term care facilities who cannot swallow.

He said that these patients often encounter more medicinal errors and problems with medication administration compared to long-term care residents who don’t face such swallowing difficulties.

Commenting on the issue, Dr. Chris Chappel, Certified Medical Director, Chappel Group Research & Chappel Senior Care, said that the risk of medication errors increases when patients face difficulty in swallowing due to crushing of medicines that should not be crushed, or from residual medication left in crushing devices.

He said that Ezallor Sprinkle’s formulation will help in administering medication for patients with common elevated lipid disorders, especially in the elderly population.

For the record, Ezallor Sprinkle is developed as an extended-release-coated capsule that can be sprinkled over soft food, can be swallowed as whole, or administered through a nasogastric tube to facilitate long-term, once-daily administration.

It combines with Kapspargo Sprinkle™ extended-release tablets as the second drug in the Sun Pharma portfolio designed specifically for individuals in long-term care.

Reports cite that Ezallor Sprinkle is contraindicated in patients with known hypersensitivity to rosuvastatin, which may include pruritus, urticaria, rash, and angioedema. Moreover, in controlled clinical trials, the most common adverse reactions with rosuvastatin were abdominal pain, asthenia, headache, myalgia, and nausea.

Source Credit: https://www.businesswire.com/news/home/20190714005038/en/Sun-Pharma-Launches-Ezallor-Sprinkle-Rosuvastatin-U.S



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Epizyme gets FDA approval for TAZVERIK™ to treat epithelioid sarcoma
Epizyme gets FDA approval for TAZVERIK™ to treat epithelioid sarcoma
By Pankaj Singh

Epizyme, Inc., a renowned biopharmaceutical company developing new epigenetic therapies, has reportedly announced that the United States Food and Drug Administration has granted the accelerated approval of the company&...

PayPal and UnionPay partner to expand their global consumer base
PayPal and UnionPay partner to expand their global consumer base
By Pankaj Singh

Digital payment applications have simplified cashless transactions by offering payment options in both offline and online mode. Within a short span of time, the digital payment industry has seen significant growth, wit...

Eli Lilly and Company to build a manufacturing unit in North Carolina
Eli Lilly and Company to build a manufacturing unit in North Carolina
By Pankaj Singh

Global pharmaceutical firm, Eli Lilly and Company has recently revealed plans to create over 460 new jobs by investing nearly $470 million in Durham, North Carolina. Reportedly, the project would introduce a brand new ...